Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 25 clinical trials
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma (PEDS-PLAN)

Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.

shortening fraction
tumor cells
bone marrow procedure
mycn protein
  • 11 Oct, 2022
  • 21 locations
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The combination may be effective because the different parts of the treatment work to strengthen the

colony stimulating factor
neutrophil count
bone marrow procedure
mycn protein
  • 04 Apr, 2023
  • 1 location
Neuroblastoma Maintenance Therapy Trial (NMTT)

difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma

colony stimulating factor
bone marrow procedure
bone metastases
monoclonal antibody ch14.18
  • 11 Jul, 2022
  • 44 locations
Neuroblastoma Biology Study

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the …

tumor cells
bone marrow procedure
  • 09 Jun, 2022
  • 13 locations
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

This is a non-interventional, multi-national, observational, prospective patient registry to further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal immunoglobulin G 1 (IgG1) antibody, to obtain information on survival, pain severity and incidence of neuro-toxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.

high-risk neuroblastoma
  • 07 Oct, 2022
  • 14 locations